Investigating Miricorilant, a Selective Glucocorticoid Receptor Modulator, for Treatment of NASH

Time: 1:00 pm
day: Seminar A- PM tracks


  • Developing miricorilant, a selective glucocorticoid receptor modulator, as a novel treatment for NASH
  • Review efficacy of miricorilant in preclinical models of fatty liver disease and early clinical trials in patients with presumed NASH
  • Next steps: Phase 2 development program for treatment of patients with non-cirrhotic NASH